

Special Issue

Botulinum Toxin for Urinary Tract Disease: After a Decade from Approval

Message from the Guest Editor

Botulinum toxin was approved by the FDA in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder. For this Special Issue, we would like to address the question of where we stand with this therapy a decade later: has it prevailed and been proven useful? Which techniques have become established, and how were they optimized? Are there more practical ways of distribution on the way? What obstacles/acceptance problems might there be from patients or doctors in (long-term) use? What are the risks, if any? Has the therapy gained a foothold in the outpatient sector?

Guest Editor

Dr. Heinrich Schulte-Baukloh

Department of Urology, and Urologic Private Practice, Charité—University Hospital Berlin, Berlin, Germany

Deadline for manuscript submissions

closed (28 February 2025)



Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed



mdpi.com/si/187514

Toxins
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
toxins@mdpi.com

[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)





Toxins

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed



[mdpi.com/journal/
toxins](https://mdpi.com/journal/toxins)



About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology, University of Virginia, Charlottesville, VA,
USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.4 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).